We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Clear Labs

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and a... read more Featured Products: More products

Download Mobile App




Clear Labs Introduces Clear Dx SARS-CoV-2 Solution that Addresses and Overcomes Traditional Barriers to NGS

By LabMedica International staff writers
Posted on 28 Sep 2021

Clear Labs (San Carlos, CA, USA) introduced its new Clear Dx SARS-CoV-2 solution that addresses and overcomes traditional barriers to next-generation sequencing (NGS) at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo which explored the cutting-edge science and technology shaping the future of laboratory medicine. More...

The Clear Dx is a fully automated, NGS platform that offers complete characterization of SARS-CoV-2 and its variants of concern. Built to deliver accurate and near real-time results, Clear Dx is revolutionizing the way clinical and public health labs approach genomic and pathogen surveillance. The fully automated sequencing platform helps labs work quickly and efficiently, offering the agility to address the rapidly evolving COVID-19 pandemic and more productive time to perform other lab tasks.

Clear Dx allows labs to generate the same outcome repeatedly - which reduces workflow errors, increases the consistency of results, boosts your overall productivity, and ultimately improves genomic surveillance. With the company’s comprehensive Clear Dx workflow, labs can manage and interpret data—and act on it accordingly—without the need for bioinformatics specialists. Featured in the platform are data integration and connectivity solutions that help to streamline pathogen surveillance of SARS-CoV-2. Clear Dx’s comprehensive and fully automated sequencing platform significantly reduces the level of effort typically required for infectious disease surveillance.

Related Links:
Clear Labs 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Automated Immunoassay Analyzer
SuperFlex™
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing

Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.